News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
Friday, August 19, 2022Jazz Pharmaceuticals plc announced it has initiated a new Phase trial to investigate the efficacy and safety of Epidiolex cannabidiol known as Epidyolex in Europe in children and adolescents with Epilepsy with MyoclonicAtonic Seizures EMAS The rando...
Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain
Friday, August 19, 2022Grnenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin RTX RTX is a highly potent Transient Receptor Potential Vanilloid TRPV agonist with a wellvalidated mechanism of...
RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections
Thursday, August 18, 2022RedHill Biopharma Ltd a specialty biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to RHB for the treatment of nontuberculous mycobacteria NTM disease following a positive opinion recommendati...
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
Thursday, August 18, 2022Aytu BioPharma Inc a pharmaceutical company focused on developing and commercializing novel therapeutics today announced that the US Patent and Trademark Office has issued a new patent No the patent for AREnzastaurin This patent titled Targeted Epi...
Bright Giant GmbH and Agilent Technologies Announce Collaboration: Innovation for Identification
Wednesday, August 17, 2022Bright Giant GmbH and Agilent Technologies are excited to announce their new product development collaboration designed to enhance nontargeted metabolomics workflows using AIbased methods and empower scientists to make novel impactful discoveries Thi...
AGAE's Pilot Plants Prove Rhamnolipid Production Breakthroughs
Wednesday, August 17, 2022AGAE Technologies LLC AGAE a specialty chemical and biotech company based in Corvallis Oregon USA is proud to announce that it is successfully operating the first fermentation and mass purification pilot plants in North America dedicated to producing...
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
Tuesday, August 16, 2022EpiAxis Therapeutics a leading epigenetics company with a focus on the treatment diagnosis and monitoring of cancer and the prevention of its recurrence and Peptilogics a biotech company engineering peptide therapeutics by combining computation and b...
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
Tuesday, August 16, 2022QIAGEN NV announced the launch of the QIAstatDx Viral Vesicular Panel RUO the first syndromic test to differentiate between monkeypox and five other pathogens which cause similar symptoms The new panel currently for research use only RUO comes in c...
WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology
Friday, August 12, 2022WuXi Advanced Therapies a wholly owned subsidiary of WuXi AppTec today announced a licensing agreement with Janssen Biotech Inc one of the Janssen Pharmaceutical Companies of Johnson Johnson Janssen Under this agreement WuXi ATU will license to Jans...
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Thursday, August 11, 2022BridgeBio Pharma Inc a commercialstage biopharmaceutical company that focuses on genetic diseases and cancers and Sentynl Therapeutics Inc Sentynl a USbased biopharmaceutical company focused on bringing innovative therapies to patients living with ra...
